Controversy over radioiodine ablation in thyroid cancer: who benefits?

Don C Yoo; Richard B Noto; Peter J Mazzaglia

doi:10.1016/j.suc.2014.03.004

Controversy over radioiodine ablation in thyroid cancer: who benefits?

Surg Clin North Am. 2014 Jun;94(3):573-86. doi: 10.1016/j.suc.2014.03.004.

Authors

Don C Yoo¹, Richard B Noto², Peter J Mazzaglia³

Affiliations

¹ Department of Diagnostic Imaging, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA. Electronic address: [email protected].
² Department of Diagnostic Imaging, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA.
³ Department of General Surgery, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA.

PMID: 24857577
DOI: 10.1016/j.suc.2014.03.004

Abstract

Recent studies have proposed that overdiagnosis is probably the principal cause of the increased incidence of thyroid cancer. The controversy around radioiodine ablation is complicated by the ever increasing numbers of small, low-risk thyroid cancers being diagnosed. This article examines the history and evolving epidemiology of the disease and treatment.

Keywords: Overdiagnosis; RIA; Radioiodine ablation; Risk stratification; Thyroid cancer.

Publication types

Review

MeSH terms

Humans
Iodine Radioisotopes / therapeutic use*
Thyroid Neoplasms / radiotherapy*
Treatment Outcome

Substances

Iodine Radioisotopes